Bafna Pharmaceuticals Financial Statements

Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar Mar-2020 Mar-2019 Mar-2018 Mar-2017
Growth matrix (%)        
Revenue growth (2) (8.10) (27) (24)
Op profit growth (109) (62) 505 (1,225)
EBIT growth (89) 108 (13) 276
Net profit growth 31 12.80 (14) 38.70
Profitability ratios (%)        
OPM 2.88 (31) (74) (8.90)
EBIT margin (4.20) (37) (16) (14)
Net profit margin (58) (44) (35) (30)
RoCE (2.80) (20) (7.20) (6.60)
RoNW (18) (17) (10) (9.70)
RoA (9.90) (5.90) (3.90) (3.60)
Per share ratios ()        
EPS -- -- -- --
Dividend per share -- -- -- --
Cash EPS (118) (9.40) (8.80) (13)
Book value per share 216 8.06 16 22.90
Valuation ratios        
P/E -- -- -- --
P/CEPS (0.10) (1.20) (3.20) (2.30)
P/B 0.04 1.36 1.75 1.29
EV/EBIDTA (2.30) (5.50) (29) (29)
Payout (%)        
Dividend payout -- -- -- --
Tax payout -- 5.84 14.90 (4.40)
Liquidity ratios        
Debtor days 133 207 302 342
Inventory days 88.90 84 106 93
Creditor days (231) (219) (116) (159)
Leverage ratios        
Interest coverage 18.70 7.60 1.12 0.77
Net debt / equity (0.10) 2.28 1.15 1.87
Net debt / op. profit (4.50) (3.30) (1.20) (14)
Cost breakup ()        
Material costs (47) (64) (81) (80)
Employee costs (24) (21) (16) (10)
Other costs (26) (46) (77) (19)
Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar( In .Cr) Mar-2020 Mar-2019 Mar-2018 Mar-2017
Revenue 42.50 43.40 47.20 65
yoy growth (%) (2) (8.10) (27) (24)
Raw materials (20) (28) (38) (52)
As % of sales 47.10 64.10 81.20 79.90
Employee costs (10) (9) (7.50) (6.80)
As % of sales 24.10 20.80 15.80 10.50
Other costs (11) (20) (37) (12)
As % of sales 25.90 45.90 77.50 18.50
Operating profit 1.22 (13) (35) (5.80)
OPM 2.88 (31) (74) (8.90)
Depreciation (3.30) (3.50) (4) (4.20)
Interest expense (0.10) (2.10) (6.90) (11)
Other income 0.26 0.65 31.30 1.14
Profit before tax (1.90) (18) (15) (20)
Taxes -- (1.10) (2.20) 0.90
Tax rate -- 5.84 14.90 (4.40)
Minorities and other (0.30) (0.50) 0.17 --
Adj. profit (2.20) (20) (17) (19)
Exceptional items (23) 1.01 -- --
Net profit (25) (19) (17) (19)
yoy growth (%) 31 12.80 (14) 38.70
NPM (58) (44) (35) (30)
Switch to
Tabular Data
Graph
Y/e 31 Mar ( In .Cr) Mar-2020 Mar-2019 Mar-2018 Mar-2017
Profit before tax (1.90) (18) (15) (20)
Depreciation (3.30) (3.50) (4) (4.20)
Tax paid -- (1.10) (2.20) 0.90
Working capital (55) (93) (94) (34)
Other operating items -- -- -- --
Operating cashflow (60) (115) (115) (58)
Capital expenditure (14) (13) (11) 2.29
Free cash flow (74) (129) (126) (55)
Equity raised 103 68.10 86.20 96.60
Investments -- -- -- --
Debt financing/disposal (82) (54) (62) 13.70
Dividends paid -- -- -- --
Other items -- -- -- --
Net in cash (54) (114) (101) 55
Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar ( In .Cr) Mar-2020 Mar-2019 Mar-2018 Mar-2017
Equity capital 57.70 23.70 23.70 22.70
Preference capital -- -- -- --
Reserves (6.60) (4.60) 14.30 20
Net worth 51.10 19.10 37.90 42.70
Minority interest
Debt 3.02 46.20 46.50 82.40
Deferred tax liabilities (net) -- 6.18 5.11 2.92
Total liabilities 54.20 71.30 88.90 127
Fixed assets 35.20 37.10 44.90 48.60
Intangible assets
Investments -- -- -- 16.90
Deferred tax asset (net) -- -- -- --
Net working capital 10.50 31.50 41 59.30
Inventories 11.40 9.28 10.70 16.70
Inventory Days 98.10 78.10 82.60 94.10
Sundry debtors 6.03 24.80 24.30 53.80
Debtor days 51.80 209 188 302
Other current assets 10.20 45.60 55.60 39.60
Sundry creditors (13) (40) (29) (24)
Creditor days 108 333 221 134
Other current liabilities (4.60) (8.70) (21) (27)
Cash 8.48 2.71 2.95 2.66
Total assets 54.20 71.30 88.90 127
Switch to
Consolidated
Standalone


Particulars ( Rupees In Crores.) Mar-2019 Mar-2018 Mar-2017 Mar-2016 Mar-2015
Gross Sales 43.40 47.20 65 85.30 97.70
Excise Duty -- -- -- -- --
Net Sales 43.40 47.20 65 85.30 97.70
Other Operating Income -- -- -- -- 41.10
Other Income 1.66 31.30 1.14 1.98 4.90
Total Income 45 78.50 66.10 87.30 144
Total Expenditure ** 56.70 82.30 70.80 84.80 118
PBIDT (12) (3.80) (4.70) 2.50 25.50
Interest 2.13 6.94 11.50 13 13.50
PBDT (14) (11) (16) (10) 12.10
Depreciation 3.48 3.97 4.22 4.86 5.99
Minority Interest Before NP -- -- -- -- --
Tax -- -- -- -- (0.20)
Deferred Tax 1.07 2.19 (0.90) (0.20) --
Reported Profit After Tax (18) (17) (19) (15) 6.22
Minority Interest After NP -- -- -- (1.10) 0.04
Net Profit after Minority Interest (18) (17) (19) (14) 6.18
Extra-ordinary Items 0.95 -- -- -- (2.80)
Adjusted Profit After Extra-ordinary item (19) (17) (19) (14) 9.01
EPS (Unit Curr.) (11) (0.10) (12) (8.80) 3.57
Book Value (Unit Curr.) -- -- -- -- --
Dividend (%) -- -- -- -- --
Equity 23.70 23.70 18.70 18.70 18.70
Public Shareholding (Number) -- -- -- -- 11,805,566
Public Shareholding (%) -- -- -- -- 63.30
Pledged/Encumbered - No. of Shares -- -- -- -- 1,397,736
Pledged/Encumbered - % in Total Promoters Holding -- -- -- -- 20.40
Pledged/Encumbered - % in Total Equity -- -- -- -- 7.49
Non Encumbered - No. of Shares -- -- -- -- 5,453,033
Non Encumbered - % in Total Promoters Holding -- -- -- -- 79.60
Non Encumbered - % in Total Equity -- -- -- -- 29.20
PBIDTM(%) (27) (8.10) (7.20) 2.93 26.10
PBDTM(%) (32) (23) (25) (12) 12.30
PATM(%) (42) (36) (30) (18) 6.37